Who Makes Generic Nivolumab?
No generic versions of nivolumab (Opdivo), Bristol Myers Squibb's PD-1 inhibitor for cancers like melanoma and lung cancer, are approved or available worldwide as of 2023. Nivolumab is a biologic monoclonal antibody, so generics aren't possible—instead, biosimilars are developed, which must demonstrate similarity in efficacy, safety, and manufacturing.[1]
When Can Biosimilars Enter the US Market?
US patent exclusivity for nivolumab extends to at least 2028, with some formulation patents lasting until 2035-2040. The main composition-of-matter patent (US 8,008,449) expires in 2028. FDA exclusivity ends December 31, 2027, but litigation from Bristol Myers Squibb has delayed biosimilar approvals. No FDA-approved nivolumab biosimilars exist yet.[2][3]
Check DrugPatentWatch.com for updated patent expiry dates and Paragraph IV challenges: DrugPatentWatch - Nivolumab Patents.
Which Companies Are Developing Nivolumab Biosimilars?
Several firms have filed abbreviated biologics license applications (aBLAs) or announced development programs, targeting post-2028 launches:
- Samsung Bioepis / Organon: Filed aBLA with FDA in 2023; decision pending after litigation. Also pursuing in Europe.
- Biocon / Mylan (Viatris): Submitted aBLA to FDA in 2022; European approval expected 2025.
- Intas Pharmaceuticals: Filed aBLA with FDA in 2023; also active in India.
- Celltrion: Advanced development, with Phase 3 trials completed; US filing planned.
- Sandoz: Early-stage program announced.
- Formycon / BioNTech: Collaborating on European biosimilar.
In Europe, EMA approvals are further along—Samsung Bioepis received positive CHMP opinion in 2024.[4][5]
Biosimilars Already Approved Outside the US
- India: Hetero Drugs launched Nimtop in 2023, the first nivolumab biosimilar.
- Other markets: Dr. Reddy's and Reliance Life Sciences have approvals or launches in select countries.[6]
How Do Nivolumab Biosimilars Compare to Opdivo?
Biosimilars match Opdivo's 240mg/10mL or 480mg/40mL dosing, with similar efficacy in trials (e.g., Samsung's showed non-inferiority in NSCLC). Pricing is 20-30% lower initially. No major safety differences reported, but switching data is limited.[7]
Sources
[1]: FDA.gov - Biologicals vs. Generics
[2]: DrugPatentWatch.com - Opdivo Patents
[3]: FDA Purple Book - Opdivo Exclusivity
[4]: Samsung Bioepis Press Release (2023)
[5]: EMA CHMP Minutes (2024)
[6]: Indian Pharma Reports (Hetero Nimtop)
[7]: Biosimilar Development Trials (Samsung Phase 3 Data)